Atanasio
Pandiella Alonso
Complejo Hospitalario Universitario de Albacete
Albacete, EspañaPublicaciones en colaboración con investigadores/as de Complejo Hospitalario Universitario de Albacete (72)
2024
-
T-reg transcriptomic signatures identify response to check-point inhibitors
Scientific Reports, Vol. 14, Núm. 1
2022
-
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
International Journal of Molecular Sciences, Vol. 23, Núm. 10
-
ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology
Cancers, Vol. 14, Núm. 14
-
Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
Cancers, Vol. 14, Núm. 18
-
Genomic mapping of copy number variations influencing immune response in breast cancer
Frontiers in Oncology, Vol. 12
-
Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis
Therapeutic Advances in Medical Oncology, Vol. 14
2021
-
Genomic mapping of splicing-related genes identify amplifications in lsm1, clns1a, and ilf2 in luminal breast cancer
Cancers, Vol. 13, Núm. 16
-
In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer
Cellular Oncology, Vol. 44, Núm. 3, pp. 569-580
-
MZ1 co-operates with trastuzumab in HER2 positive breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1
-
Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation
International Journal of Molecular Sciences, Vol. 22, Núm. 8
2020
-
An overview of antibody conjugated polymeric nanoparticles for breast cancer therapy
Pharmaceutics, Vol. 12, Núm. 9, pp. 1-20
-
Antibody conjugation of nanoparticles as therapeutics for breast cancer treatment
International Journal of Molecular Sciences, Vol. 21, Núm. 17, pp. 1-21
-
Checkpoint kinase 1 pharmacological inhibition synergizes with dna-damaging agents and overcomes platinum resistance in basal-like breast cancer
International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-14
-
Genomic mapping identifies mutations in ryr2 and ahnak as associated with favorable outcome in basal-like breast tumors expressing pd1/pd-l1
Cancers, Vol. 12, Núm. 8, pp. 1-15
-
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer
Cancer Letters, Vol. 491, pp. 50-59
-
Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer
Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 5, pp. 3117-3127
2019
-
A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
Frontiers in Immunology, Vol. 10
-
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1
-
Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors
PLoS ONE, Vol. 14, Núm. 4
-
Screening and preliminary biochemical and biological studies of [RuCl(p-cymene)(N, N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models
ACS Omega, Vol. 4, Núm. 8, pp. 13005-13014